Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: An open-label pilot study

Annals of Internal Medicine

Volumn 161, Issue 9, 2014, Pages 634-638

  Osinusi, Anu ^a   Kohli, Anita ^b   Marti, Miriam M ^c   Nelson, Amy ^b   Zhang, Xiaozhen ^b   Meissner, Eric G ^c   Silk, Rachel ^c   Townsend, Kerry ^d   Pang, Phillip S ^a   Subramanian, G Mani ^a   McHutchison, John G ^a   Fauci, Anthony S ^b   Masur, Henry ^b   Kottilil, Shyam ^b  

^a GILEAD SCIENCES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c 10/11N204 ^*  (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; URIDINE PHOSPHATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERCHOLESTEROLEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KNODELL HISTOLOGY ACTIVITY INDEX; LIVER DISEASE; LOOSE FECES; MALE; MYALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NOSE OBSTRUCTION; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRURITUS; RASH; RELAPSE; SAMPLE SIZE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MUTATION; RECURRENT DISEASE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; RECURRENCE; RIBAVIRIN; RNA, VIRAL; URIDINE MONOPHOSPHATE;

EID: 84919342996     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1211     Document Type: Article

References (25)

1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-21, 521.e1-6. [PMID: 19861128] doi:10.1053/j.gastro.2009.09.067
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-8. [PMID: 22351712] doi: 10.7326/0003-4819-156-4-201202210-00004
3. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Oncedaily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013; 58:1918-29. [PMID: 23907700] doi:10.1002/hep.26641
4. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34-44. [PMID: 23281974] doi:10.1056 /NEJMoa1208953
5. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection [Letter]. N Engl J Med. 2013;369:678-9. [PMID: 23944316] doi: 10.1056/NEJMc1307641
6. Olysio [package insert]. Titusville, NJ: Jannsen Products; November 2013. Accessed at www.olysio.com/shared/product/olysio/prescribing-information.pdf on 20 August 2014.
7. Sovaldi [package insert]. Foster City, CA: Gilead Sciences; December 2013. Accessed at www.gilead.com/-/media/Files/pdfs/medicines/liver-disease/sovaldi /sovaldi-pi.pdf on 20 August 2014.
8. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804-11. [PMID: 23982366] doi:10.1001/jama.2013.109309
9. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, Fessel WJ, Mounzer K, Shuhart, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology. 2013;58(S1):313A.
10. Curry MP, Forns X, Chung RT, Terrault N, Brown RS, Fenkel JM, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology. 2013;58(S4):314A-5A.
11. Charlton MR, Gane EJ, Manns MP, Brown RS, Curry MP, Kwo P, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective multicenter study. Hepatology. 2013;58(S4):Abstr LB-2.
12. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-93. [PMID: 24725238] doi: 10.1056/NEJMoa1316366
13. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98. [PMID: 24725239] doi:10.1056 /NEJMoa1402454
14. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-88. [PMID: 24720702] doi:10.1056/NEJMoa1402355
15. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014; 383:515-23. [PMID: 24209977] doi:10.1016/S0140-6736(13)62121-2
16. Cheng G, Peng B, Corsa A, Yu M, Nash M, Lee YJ, et al. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885 [Abstract]. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, 18-22 April 2012. Abstract 1172.
17. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5. [PMID: 7308988]
18. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359-68. [PMID: 22430955] doi:10.1128/AAC.00054-12
19. Lam AM, Espiritu C, Murakami E, Zennou V, Bansal S, Micolochick Steuer HM, et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug ofβ-D-2'-deoxy-2'-a-fluoro-2'-β-Cmethylguanosine. Antimicrob Agents Chemother. 2011;55:2566-75. [PMID: 21444700] doi:10.1128/AAC.00032-11
20. Le Pogam S, Jiang WR, Leveque V, Rajyaguru S, Ma H, Kang H, et al. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology. 2006;351:349-59. [PMID: 16713611]
21. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem. 2003;278:49164-70. [PMID: 12966103]
22. Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther. 2012;17:411-23. [PMID: 22402762] doi:10.3851/IMP2088
23. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012;57:24-31. [PMID: 22314425] doi:10.1016/j.jhep.2011.12.029
24. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641-50. [PMID: 20585111] doi: 10.1128/AAC.00556-10
25. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013;10: 355. [PMID: 24341898] doi:10.1186/1743-422X-10-355